<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131088">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01863277</url>
  </required_header>
  <id_info>
    <org_study_id>0130-12</org_study_id>
    <nct_id>NCT01863277</nct_id>
  </id_info>
  <brief_title>Safety Study of Melatonin in Stroke Patients</brief_title>
  <official_title>A Double Blind, Placebo Controlled Study to Evaluate the Efficacy of Melatonin in Acute Ischemic Stroke.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wolfson Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wolfson Medical Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effect of Melatonin (in a dosage of 14mg daily)
      for a better clinical outcome in the period three days post stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stroke is the third most common cause of stroke. The cascade of event is separated into
      hyperacute,,acute,sub-acute and chronic. In the acute, sub acute state there are mechanisms
      of inflammation apoptotic death and effect of free radicals. Melatonin was proved to effect
      these mechanisms and to have a favourable effect in different diseases. The aim of the study
      is to prove That the use of Melatonin in a higher dosage may have a anti-destructive effect
      in stoke.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improvement of at least one point on the MRS score</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Melatonin 14mg/daily given over 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sugar pill given over 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>none</description>
    <arm_group_label>Melatonin</arm_group_label>
    <other_name>Melatonin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  within 72hours of ischemic stroke

          -  age 18-80

          -  both gender

          -  ability to sign consent form

        Exclusion Criteria:

          -  intra-cerebral bleeding

          -  tumour of brain

          -  multiple sclerosis

          -  s/p craniotomy

          -  known allergy to melatonin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>E. Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yair Lampl, Prof</last_name>
      <phone>+972-3-5028513</phone>
      <email>y_lampl@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mary Israelson</last_name>
      <phone>+972-507-704618</phone>
      <email>maryisraelson@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yair Lampl, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>May 24, 2013</lastchanged_date>
  <firstreceived_date>May 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wolfson Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Yair Lampl</investigator_full_name>
    <investigator_title>Prof. Yair Lampl</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
